GSK Investigational Site
Liucheng County, Guangxi, 545200, China
NCT Number: NCT01086436
The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy children aged 2 to 6 years in China.
Looking for future studies?
Notify Me2 year–6 year
All sexes
Interventional
Phase 1
Liucheng County, Guangxi, 545200, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral, single dose
Oral, single dose
Time frame: Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose.
Time frame: Within the 31 days (Day 0 - Day 30) after the vaccine dose.
Time frame: Throughout the study period following the vaccine dose.
GlaxoSmithKline
Industry
Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03954743
Infections, Infections, Rotavirus
Birmingham, Alabama, United States
View Trial DetailsNCT00353366
Digestive System Diseases, Gastroenteritis
Alabang, Muntinlupa City, Philippines
View Trial DetailsNCT00263666
Infections, Infections, Rotavirus
Attridgerville, Gauteng, South Africa
View Trial DetailsNCT02914184
Infections, Infections, Rotavirus
Birmingham, Alabama, United States
View Trial Details